Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”) is pleased to announce that our flagship comprehensive genomic profiling (CGP) product, OncoScreenTM Plus, was featured in a phase 3 multi-regional clinical trial (MRCT), along with FoundationOneCDx, in support of advancement in breast cancer treatment.

Pfizer and Thermo Fisher Scientific Inc. announced they have entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients in more than 30 countries across Latin America, Africa, the Middle East and Asia.

Sysmex Europe and Cerca Biotech said Monday that they have inked a deal for Sysmex to distribute Cerca's molecular breast cancer assay in 13 European markets.

Precision oncology company Guardant Health announced on Monday that FDA has approved its Guardant360 CDx liquid biopsy test as a companion diagnostic.

Aiforia Technologies said Wednesday that it has received CE-IVD marking for an artificial intelligence model that helps detect progesterone-positive tumor cells.

Liquid biopsy performed on serum samples taken from breast cancer patients can provide increasingly accurate information on cancer progression and enable earlier detection of cancer recurrence, a new study from the University of Eastern Finland and Kuopio University Hospital shows.

Imagine getting a positive result on a genetic test. The doctor tells you that you have a “pathogenic genetic variant,” or a DNA sequence that is known to raise the chances for getting a disease like breast cancer or diabetes.

Agilent Technologies Inc. today announced its Ki-67 IHC MIB-1 pharmDxis now FDA approved as an aid in identifying patients with early breast cancer at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.

Researchers have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood are critical indicators for the prediction of disease recurrence and disease-free survival.